株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

医薬品受託製造機関 (CMO) 産業の定量的分析:企業構成、市場規模、市場シェア、将来展望

PharmSource - Contract Dose Manufacturing Industry by the Numbers: Composition, Size, Market Share and Outlook - 2019 Edition

発行 GlobalData 商品コード 409612
出版日 ページ情報 英文 42 Pages
即納可能
価格
本日の銀行送金レート: 1USD=111.33円で換算しております。
Back to Top
医薬品受託製造機関 (CMO) 産業の定量的分析:企業構成、市場規模、市場シェア、将来展望 PharmSource - Contract Dose Manufacturing Industry by the Numbers: Composition, Size, Market Share and Outlook - 2019 Edition
出版日: 2019年10月30日 ページ情報: 英文 42 Pages
概要

当レポートでは、世界の医薬品 (最終製剤) 向け医薬品受託製造機関 (以下CMO) の業界動向について分析し、CMOの企業数・市場規模・市場シェアの推移や、地域別・分野別 (剤型別) の分布傾向、昨今の資本取引動向、今後の業界動向の見通しなどについて調査しております。

目次

  • エグゼクティブ・サマリー
  • 産業構造・規模
  • 産業規模と成長率
  • CMO (医薬品受託製造機関) の市場シェア
  • 医薬品CMO業界の将来展望
  • 付録
  • 市場規模・成長率の推計方法

表の一覧

  • 表1 CMOによる施設買収活動の概略 (2012年~)
  • 表2 CMOによる (バイオ) 製薬企業の生産施設の買収
  • 表3 CMOによる他のCMOの買収
  • 表4 主要CMOの一部分野からの撤退
  • 表5 CMO業界での、昨今のプライベートエクイティ投資活動
  • 表6 医薬品CMO業界でのプライベートエクイティ投資活動 (2011年~)
  • 表7 主要CMOの収益額比較 (2012年~)

図の一覧

  • 図1 医薬品CMOの地域別の分布状況
  • 図2 医薬品CMOの内訳:収益額別 (CMOの件数)
  • 図3 医薬品CMOの市場規模 (2009年~)
  • 図4 医薬品CMOの剤型別の内訳 (金額ベース)
  • 図5 医薬品CMOの市場シェア:企業規模別
  • 図6 FDA (米国食品医薬品局) によるNDA (新薬承認申請書) の認証件数:2010年以降
  • 図7 世界の (バイオ) 医薬品企業の外注化傾向 (2006年~)
  • 図8 FDAによる奇病向け新規分子化合物 (NME) の認証件数:2010年以降
  • 図A1 分析対象企業数の増減
図表

List of Tables

  • Table 1: Summary of CMO Facility Acquisition of Dose Facilities Activity, 2013-2018
  • Table 2: CMO Acquisitions of Dose Manufacturing Facilities, 2018
  • Table 3: Dedicated CMO Acquisitions of Companies with Commercial Dose Capabilities, 2018
  • Table 4: PE Investments in the Dose CMO Industry, 2013-2018
  • Table 5: Percentage of Commercial Dose Facilities that Offer Other Services, by Revenue Tier
  • Table 6: Revenue Composition and Strategic Orientation of Leading CMOs, 2018
  • Table 7: Geographical Reach of Dose CMO Universe, 2018

List of Figures

  • Figure 1: Geographic Reach of the Dose CMO Universe, 2018
  • Figure 2: Geographic Distribution of Commercial Dose Facilities, 2018
  • Figure 3: Geographic Distribution of Commercial Dose Injectable Facilities, 2018
  • Figure 4: Dose CMO Count by Revenue Tiers, 2018
  • Figure 5: Dose CMO Market Size by Revenue, 2009-2018
  • Figure 6: Components of Growth for Dose CMOs, 2017-2018
  • Figure 7: Dose CMO Dosage Form Revenue Segments in 2018 ($B)
  • Figure 8: Headquarters Locations of $0-12M Revenue Tier CMOs
  • Figure 9: Dosage Forms Manufactured for $0-12M Revenue Tier CMOs
  • Figure 10: Dose CMO Industry Market Share by Company Revenue Tier, 2018
  • Figure 11: Bio/Pharma Services Sector Performance
  • Figure 12: Organic Revenue Growth for Public CMOs
  • Figure 13: Mega Cap Outsourcing Propensity 2008-2018
  • Figure 14: Outsourcing of Orphan NMEs 2009-2018
目次
Product Code: GDPS0027MAR

The motivation for pharma companies outsourcing their manufacturing is often to do with lacking expertise, equipment, or cost reduction (especially for small to mid-sized CMOs) in development of their product's API or dose. For clinical dose manufacturing, there is a high risk associated with the pipeline drug product and as such using a CMO for this mitigates risk for pharma companies that may otherwise have to invest in equipment and facilities.

This report, the 2019 version in this annual series, characterizes the contract dose manufacturing industry along a number of quantitative dimensions, including number and type of participants, market size, market shares of the top CMOs and profitability. We also assess the outlook for the industry. This report is an improvement over previous reports because it utilizes the integration of Dose manufacturing integration into the GlobalData's Pharma Intelligence Center to provide deeper analysis of the industry.

This expert trend report is a comprehensive look at the finished dose contract manufacturing landscape in 2019, including analysis of dose CMO M&A activity, market size and share. It is a critical source for strategic planning efforts and will improve understanding of crucial components of the supply chain that will provide insights for supplier selection and management.

Scope

  • This report gives an important expert quantitative analysis on the contract dose manufacturing industry. Findings are based on the industry's most comprehensive database of the dose CMO industry (GlobalDatas Contract Service Providers Database) this analysis is driven by a proprietary model of the dose manufacturing industry, which is continuously updated and refined. The 7 tables and 14 figures throughout the report illustrate major points and trends. This report is required reading for -
  • CMO executives and strategic decision-makers: improves understanding of the dose CMO industry and a critical input for strategic planning efforts.
  • Sourcing and procurement executives in bio/pharmaceutical companies: improving understanding of crucial components of the supply base that will provide insights for supplier selection and management.
  • Private equity investors: they can deeper understanding of the dose CMO market and important insight for identifying potential investment targets.

Reasons to buy

  • What is the geographic reach of Dose CMOs?
  • What are the 2018 revenues generated by Contract dose manufacturing industry?
  • What are the components of revenue change for Contract Dose Manufacturers?
  • What is the breakdown of 2018 revenues by different dosage forms?
  • What are the characteristics of the largest dose CMOs?
  • How did the revenue growth of Contract Dose manufacturers in 2018 compare to Contract API manufacturers? - What is the outlook for the dose CMO industry?
  • What Dose CMO M&A deals occurred in 2018?

Table of Contents

  • List of Tables
  • List of Figures
  • Executive Summary
  • Industry Size and Structure
  • Major Developments Affecting Industry Structure
  • Industry Size and Growth CMO Market Shares
  • Analyzing Recent Dose CMO Industry Performance
  • Appendix
Back to Top